The European Biotech Act: A Turning Point for EU Health Biotechnology

On 16 December 2025, the European Commission adopted a landmark legislative proposal — the European Biotech Act — as part of a wider package of measures to modernize the EU’s health and healthcare ecosystem. This initiative aims to position Europe as a global leader in biotechnology and biomanufacturing, with a strong focus on strengthening competitiveness, reducing regulatory complexity, and accelerating market access for biotech innovations. 

The explanatory memorandum to the Biotech Act highlights the strategic importance of biotechnology to the EU’s economy, public health, and scientific leadership. Despite robust research output and world-class science, Europe has struggled to translate innovation into commercial success and scaled biomanufacturing, often losing high-potential start-ups and projects to other regions with more dynamic regulatory and capital markets. 

Biotechnology today contributes significantly to the EU’s GDP and employment — particularly in health biotech — but structural barriers in clinical development, regulation, and manufacturing have hindered growth and innovation relative to the U.S. and Asia. The Biotech Act is designed to address these gaps and promote growth across the full innovation lifecycle. 

Core Objectives of the Biotech Act 

Stakeholder feedback during the Biotech Act’s development underscored major regulatory bottlenecks, especially around lengthy authorization processes, fragmented national procedures, and complexity in adapting to cutting-edge technologies. The Act’s proposals — including harmonized requirements and controlled regulatory sandboxes — reflect a concerted effort to reduce uncertainty and encourage innovation across the lifecycle from research through commercialization. By amending and aligning key existing EU regulations (including medical devices, clinical trials and advanced therapies), the primary goals include: 

• Boosting Innovation and Investment 
  A dedicated health biotech investment pilot with the European Investment Bank Group aims to mobilize up to €10 billion in public and private funding to support biotech ventures from early R&D through to scale-up and manufacturing. This reflects a strategic emphasis on closing Europe’s funding gap and reducing reliance on foreign capital. 

• Streamlining Regulation and Time to Market 
  The proposal includes simplification and harmonization of regulatory pathways across Member States — particularly in cross-border clinical trial authorizations, early engagement with regulators, and regulatory sandboxes for breakthrough technologies that need tailored oversight. 

• Enhancing Strategic Autonomy and Industrial Capacity 
  With targeted support for biomanufacturing, including centers of excellence and biosecurity infrastructure, the Act intends to strengthen Europe’s ability to produce advanced therapies and complex biologics domestically. 

• Ensuring Safety and Biosecurity 
  Alongside opportunities for innovation, the Act proposes biosecurity safeguards to protect against misuse of biotechnology and enhance biodefense preparedness — an increasingly critical consideration in regulatory frameworks. 

Regulation and Directive Components – Key Changes and Examples 

The European Biotech Act is a coordinated legislative package composed of three interlinked proposals. Together, they aim to modernize the EU regulatory framework for biotechnology across medicines, devices/diagnostics, and specific biotech activities, while reducing fragmentation and regulatory burden for innovators and sponsors. 

1. Biotech Framework Regulation (COM(2025)1022) 

This proposed Regulation establishes an overarching framework to strengthen the Union’s biotechnology and biomanufacturing sectors, with a strong focus on health applications. Rather than replacing existing sectoral legislation, it introduces targeted amendments that better align existing EU rules and improve coherence and efficiency across the development lifecycle. 

Key proposed changes include, for example: 

• Introduction of a “core dossier”: 

To address repeated submission of the same data across regulatory procedures, the Regulation introduces the concept of a core dossier for investigational medicinal products. This core set of scientific and regulatory information may be reused across multiple related procedures (e.g. clinical trial authorizations, subsequent development phases, or related applications), reducing administrative burden and facilitating more efficient regulatory reviews. 

• Reduced and more predictable review timelines: 

By simplifying procedures and improving coordination between authorities, the Regulation seeks to shorten and stabilize review timelines, particularly for clinical development activities conducted in more than one Member State. This responds to long-standing concerns from sponsors about delays driven by fragmented national processes rather than scientific issues. 

• Early and coordinated regulatory support: 
  The proposal establishes EU-level support structures to help developers clarify regulatory status and applicable requirements at earlier stages of development — particularly relevant for complex products such as advanced therapies or novel biologics that do not fit neatly into existing categories. 

• Recognition of strategic biotech projects: 
  Certain health biotech and biomanufacturing projects may be designated as “strategic”, enabling priority administrative treatment and coordinated support where they contribute to EU health security, innovation capacity, or manufacturing resilience. 

These measures are intended to address long-standing concerns around regulatory unpredictability and fragmentation, especially for sponsors operating across multiple Member States. 

1. Regulation Amending MDR and IVDR (COM(2025)1023) 

As part of the Biotech Act, the Commission also proposes targeted amendments to the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Medical Devices Regulation (IVDR). These changes are designed to support innovation while addressing implementation challenges under both frameworks. 

Examples of proposed changes include: 

• More proportionate regulatory requirements: 
  The proposal introduces adjustments to make certain obligations under MDR and IVDR more risk-based, particularly where current requirements have proven disproportionate for low-risk or well-understood technologies. 

• Improved feasibility for diagnostics and combination products: 
  Amendments aim to ease bottlenecks affecting in vitro diagnostics — including those used as companion diagnostics or within clinical trials — which are often critical to biotech drug development strategies. 

• Greater regulatory flexibility over the product lifecycle: 
  The proposal clarifies rules around changes to devices after certification and certain post-market obligations, helping manufacturers manage innovation and iteration without triggering unnecessary regulatory disruption. 

For biotech sponsors, these changes are particularly relevant where therapeutic development depends on integrated diagnostic or device components. 

1. Directive on Genetically Modified Micro-oOrganisms and Organ-Related Activities (COM(2025)1031) 

The accompanying Directive addresses more specific areas of biotechnology regulation that remain subject to significant national divergence. 

Key elements include: 

• Harmonized rules for placing genetically modified micro-organisms on the market: 
  The Directive seeks to align national approaches and reduce legal uncertainty for developers working with genetically modified micro-organisms in health and biotech applications. 

• Updated safety and oversight requirements: 
  It modernizes provisions on risk assessment, traceability, and control measures to reflect current scientific and technological developments, while maintaining a high level of protection for public health. 

Taken together, these three instruments illustrate the Commission’s intent to move away from siloed regulation and toward a more integrated, innovation-friendly biotech regulatory ecosystem — spanning medicines, devices, diagnostics, and enabling technologies. 

Next Steps and Legislative Outlook 

The Biotech Act proposal has been formally submitted to the European Parliament and the Council of the EU under the ordinary legislative procedure. Debate and amendment in both institutions will shape the final text, with stakeholders encouraged to engage through ongoing consultations and industry associations. If adopted, the different elements of the Biotech Act are likely to enter into force in stages, with Regulations applying directly across the EU after a defined transition period, and Directives requiring transposition into national law. 

Despite the fact that tangible regulatory changes will unfold gradually and are unlikely to be fully felt for several years, the Biotech Act represents a significant strategic shift in how the EU approaches biotechnology regulation. Its eventual adoption is poised to bring fundamental and long-lasting changes to the EU biotech landscape, enhancing innovation, streamlining development pathways, and strengthening Europe’s global competitiveness. 

How Boyds can help 

Navigating the European Biotech Act and its associated regulatory changes will require early, strategic engagement and a clear understanding of how evolving EU frameworks apply to individual development programs. Boyds provides expert, end-to-end regulatory and development support across the biotech lifecycle — from early strategy and regulatory classification through to clinical development, manufacturing readiness, and market access. 

Our multidisciplinary team works closely with biotech innovators and sponsors to interpret emerging legislation, assess its practical impact on development plans, and design robust regulatory strategies that reduce risk, streamline approvals, and support efficient progression to market. If you would like to discuss how the European Biotech Act may affect your program, or how to prepare for upcoming regulatory changes, please get in touch to speak with one of our experts.